Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $24.81

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given a consensus recommendation of “Hold” by the twenty-four research firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $24.8095.

Several research firms recently commented on SRPT. Oppenheimer restated an “outperform” rating and set a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Royal Bank Of Canada increased their target price on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research note on Tuesday, April 7th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, June 29th. Wall Street Zen upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th.

Sarepta Therapeutics Trading Up 3.2%

Shares of Sarepta Therapeutics stock opened at $19.79 on Friday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $25.32. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -20.61, a PEG ratio of 0.20 and a beta of 0.21. The firm’s 50 day simple moving average is $17.81 and its two-hundred day simple moving average is $19.29.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business posted ($3.42) earnings per share. Analysts predict that Sarepta Therapeutics will post 3.95 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently made changes to their positions in SRPT. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics during the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Ancora Advisors LLC increased its stake in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the last quarter. Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.